Integra LifeSciences Holdings Corporation (NASDAQ:IART) reported fourth-quarter results on Thursday that came in ahead of Wall Street estimates, although weaker near-term guidance tempered investor optimism despite a modest after-hours share gain.
The medical technology company posted adjusted earnings per share of $0.83, topping analyst expectations of $0.80. Revenue totaled $434.9 million, slightly above the consensus estimate of $429.63 million but down 1.7% from $442.6 million recorded a year earlier. On an organic basis, revenue declined 2.5%.
Shares rose 1.64% in after-hours trading following the announcement.
Looking ahead, Integra forecast first-quarter 2026 adjusted earnings per share between $0.37 and $0.45, with the midpoint of $0.41 significantly below analyst expectations of $0.48. The company also projected first-quarter revenue of $375 million to $390 million, implying a midpoint of $382.5 million, short of the $392.1 million consensus estimate.
For the full year 2026, Integra expects adjusted EPS of $2.30 to $2.40, with the midpoint of $2.35 broadly in line with market forecasts. Annual revenue is projected between $1.66 billion and $1.7 billion, with the midpoint of $1.68 billion slightly ahead of the $1.67 billion consensus.
“In the fourth quarter, we drove tangible operational progress while continuing to deliver for our customers and patients,” said Mojdeh Poul, president and chief executive officer. “During 2025, we further strengthened our quality management system, advanced our Compliance Master Plan, and progressed execution of our remediation work.”
Segment performance was mixed during the quarter. The Codman Specialty Surgical division, which accounts for roughly 75% of total revenue, grew 2.7% year over year to $323.3 million. Meanwhile, the Tissue Technologies segment declined 12.8% to $111.6 million, primarily reflecting remediation activities related to MediHoney and difficult comparisons tied to Integra Skin products.